Bone biology and the pathogenesis of osteoporosis

Current Opinion in Rheumatology

Volumn 18, Issue SUPPL. 1, 2006, Pages

  Russell, R Graham G ^a   Espina, Belen ^a   Hulley, Philippa ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Ageing; Bone; Osteoblasts; Osteoclasts; Osteoporosis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM SENSING RECEPTOR; MEVALONIC ACID; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE;

BONE CELL; BONE DEVELOPMENT; BONE FRAGILITY; BONE MASS; BONE METABOLISM; BONE REMODELING; BONE TURNOVER; CALCIUM METABOLISM; CELL DIFFERENTIATION; CELL FUNCTION; CLINICAL TRIAL; CONFERENCE PAPER; FRACTURE; HEREDITY; HUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; RISK ASSESSMENT;

AGING; BONE AND BONES; HUMANS; OSTEOBLASTS; OSTEOCLASTS; OSTEOPOROSIS;

EID: 33747887309     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.bor.0000229521.95384.7d     Document Type: Conference Paper

References (25)

1. Kronenberg HM. Genetically altered mice for bone research. J Musculoskeletal Neuronal Interact 2005; 5:348-349.
2. Horton WA. Recent milestones in achondroplasia research. Am J Med Genet 2006; 140:166-169.
3. Kronenberg HM. Developmental regulation of the growth plate. Nature 2003; 423:332-336.
4. Kobayashi T, Kronenberg H. Minireview: transcriptional regulation in development of bone. Endocrinology 2005; 146:1012-1017.
5. Poole KE, van Bezooijen RL, Loveridge N, et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 2005; 19:1842-1844.
6. Bellido T, Ali AA, Gubrij I, et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 2005; 146:4577-4583.
7. Lazner F, Gowen M, Pavasovic D, Kola I. Osteopetrosis and osteoporosis: two sides of the same coin. Hum Mol Genet 1999; 8:1839-1846.
8. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003; 423:337-342.
9. McClung MR, Lewiecki EM, Cohen SD, et al. AMG 162 Bone Loss Study Group. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006; 354:860-863.
10. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000; 21:115-137.
11. Power J, Noble BS, Loveridge N, et al. Osteocyte lacunar occupancy in the femoral neck cortex: an association with cortical remodeling in hip fracture cases and controls. Calcif Tissue Int 2001; 69:13-19.
12. Takeda S, Elefteriou F, Levasseur R, et al. Leptin regulates bone formation via the sympathetic nervous system. Cell 2002; 111:305-317.
13. Russell RGG. Pathogenesis of osteoporosis. In: Hochberg MC, Silman AJ, Smolen SJ, Weinblatt ME, Weisman MH, editors. Rheumatology, 3rd ed. New York: Mosby; 2003. pp. 2075-2147.
14. National Osteoporosis Society UK (www.nos.org.uk) and National Osteoporosis Foundation USA (www.nof.org). Accessed: May 2006
15. Cooper C, Westlake S, Harvey N, et al. Review: developmental origins of osteoporotic fracture. Osteoporos Int 2006; 17:337-347.
16. Boyden LM, Mao J, Belsky J, et al. High bone density due to a mutation in LDL-receptor-related protein. N Engl J Med 2002; 346:1513-1521.
17. Little RD, Carulli JP, Del Mastro RG, et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 2002; 70:11-19.
18. Ralston SH. Genetic control of susceptibility to osteoporosis. J Clin Endocrinol Metab 2002; 87:2460-2466.
19. Riggs BL, Parfitt AM. Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling. J Bone Miner Res 2005; 20:177-184.
20. Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004; 350:1189-1199.
21. Boonen S, McClung MR, Eastell R, et al. Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old. J Am Geriatr Soc 2004; 52:1832-1839.
22. Russell RGG, Rogers MJ. Bisphosphonates From the laboratory to the clinic and back again. Bone 1999; 25:97-106.
23. Russell RGG. Bisphosphonates: from bench to bedside. In: Zaidi M, editor. Skeletal development and remodeling in health, disease and aging. Ann NY Acad Sci 2006; in press.
24. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344:1434-1441.
25. Meunier PJ, Slosman DO, Delmas PD, et al. Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis - a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 2002; 87:2060-2066.